Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

J&J's (JNJ) competitors in COVID-19 vaccine space are anticipated to gain from suspension of its vaccine in the United States, following very few cases of blood clots.

Is J&J's COVID-19 Vaccine Setback a Boon for Other Players?

Johnson & Johnson's (NYSE:JNJ) stock gapped down 3% Tuesday following the Food and Drug Administration and the Centers for Disease Control and Prevention's recommendation that the use of its COVID-19 vaccine be paused in the U.S. Reports show that of the 6.8 million individuals who have received the vaccine so far, six have suffered a rare type of blood clotting.

Bulls Bought The Dip In Johnson & Johnson Stock: What's Next?

The Advisory Committee on Immunization Practices will review data on the women who developed a rare blood-clotting disorder.

CDC panel to debate use of J&J Covid vaccine after rare blood clot issue affects 6 women

Europe's medicines regulator on Wednesday said it still believes the benefits of Johnson & Johnson's Covid-19 vaccine outweigh the risks of side effects.

EU medicines regulator says benefits of J&J vaccine outweigh risks as it reviews rare blood clots

The Office of the Illinois State Treasurer is calling on Johnson & Johnson shareholders to reject Chief Executive Alex Gorsky's $29.6 million pay package because it shields him from the U.S. healthcare company's opioid litigation costs.

J&J investor calls on shareholders to reject CEO Gorsky's pay

AstraZeneca

BioNTech SE

Moderna

Pfizer

A comparison between COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX), Moderna's (MRNA), AstraZeneca (AZN) and J&J (JNJ) is inevitable.

Which Vaccine Maker Will Win the Fight Against COVID-19?

FDA/CDC said that rare and severe blood clots accompanied by low levels of blood platelets have been identified in six individuals who received J&J's (JNJ) COVID-19 vaccine.

J&J (JNJ) COVID-19 Jab to be Paused on FDA/CDC Recommendation

BTIG digital services analyst Jake Fuller does not see a long-term impact on travel from the latest obstacles in the vaccine rollout. He explains why.

Three reasons any J&J vaccine pause may not 'derail the inevitable' for travel industry

Could Johnson & Johnson Be a Big Winner in the Flu Vaccine Market?

Here's what you'll want to know about the impact of the potential safety issues with the one-dose coronavirus vaccine.

Johnson & Johnson's COVID Vaccine Paused: 5 Answers to Your Questions

AstraZeneca PLC (LON:AZN) and Johnson & Johnson (NYSE:JNJ) are not expected to get their COVID-19 vaccine contracts renewed by the EU Commission. The bloc is planning to focus on mRNA-based vaccines, such as those produced by Pfizer and Moderna, Italian newspaper La Stampa reported.

AstraZeneca, Johnson & Johnson not expected to have COVID-19 vaccine contracts renewed by EU

A former FDA official talks about how the agency makes these decisions and what it means for the fight to end the COVID-19 pandemic.

Why Pause The J&J Vaccine? An Expert Explains The Decision

Federal health officials say the ultra-rare blood clots reported in six people who received Johnson & Johnson's COVID-19 vaccine are similar to blood clots detected in a very small number of people in Europe who were immunized with AstraZeneca's shot.

Rare blood clots tied to J&J's COVID-19 shot are similar to issues with AstraZeneca's vaccine, FDA official says

The race to immunize the world against the coronavirus is now facing its biggest safety-related challenge yet. Two leading vaccines, developed by Johnson & Johnson and by AstraZeneca, have now seen their rollouts disrupted by concerns that they cause very rare but serious cases of blood clotting.

Doctors say fears of blood clots from J&J's shot are overdone and could delay the push to end the pandemic

Johnson & Johnson's corporate bonds are trading lower across the board Tuesday, after two leading U.S. health agencies recommended a pause on its one-shot COVID-19 vaccine after six vaccinated women developed blood clotting.

Market Extra: J&J debt trades lower after pause of one-shot COVID-19 vaccine

The news that Johnson & Johnson (JNJ) has been forced to pause its Covid-19 vaccine rollout  is giving several other vaccine frontrunners a boost in today's  trading.

JNJ Drama Drives Option Bulls to Sector Peer

The Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) handed down a recommendation to pause the use of Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine. In a joint audio press conference hosted by Acting FDA Commissioner Janet Woodcock, FDA Center for Biologics Evaluation and Research Director Peter Marks and CDC Principal Deputy Director Anne Schuchat, the agencies explained the motive behind the action and potential timeline for resolution, among other things.

FDA, CDC Officials Discuss Johnson & Johnson Vaccine: A 'Pause Recommendation', Resolution Timeline And Advisory

White House chief medical advisor Dr. Anthony Fauci said the FDA's recommended pause will give U.S. health regulators the time they need to thoroughly investigate how six women developed a rare blood clotting disorder that left one dead.

Dr. Anthony Fauci explains what the U.S. 'pause' on J&J's Covid vaccine means

The warning from U.S. officials to states is likely to fuel more hesitancy in taking J&J's shot and other vaccines, threatening to stall the pandemic recovery.

More people likely won't want J&J's Covid vaccine following latest issues with blood clots

Johnson & Johnson (NYSE:JNJ) shares are trading lower amid a pause on its COVID-19 vaccine due to rare blood clot cases in some patients. Johnson & Johnson was trading down 1.6% to $159 at publication time.

Technicals To Watch As Johnson & Johnson Pauses Vaccine After Blood Clot Cases

What blood clot symptoms should you watch out for? Should you cancel your upcoming vaccine appointment?

The Margin: Johnson & Johnson vaccine pause: What to know if you got or scheduled the shot

CNN's chief medical correspondent Dr. Sanjay Gupta reports on Johnson & Johnson and the CDC announcing their recommendation to "pause" the use of the Johnson & Johnson vaccine out of an abundance of caution.

Dr. Gupta: Johnson & Johnson vaccine pause will fuel hesitancy

If you got the J&J Covid vaccine, here are symptoms of blood clotting and low blood platelets that you should know about—but the complication is extremely rare.

What Johnson & Johnson Covid vaccine's rare blood clotting issues means for you — and symptoms to look out for

The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices is scheduled to hold an emergency meeting on Wednesday, starting at 1:30 p.m. Eastern Time, in response to a federal recommendation made Tuesday to temporarily halt immunizations using Johnson & Johnson's COVID-19 vaccine.

CDC committee to hold emergency meeting for J&J's COVID-19 shot on Wednesday afternoon

Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Johnson & Johnson Stock (JNJ)